Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZZW-115 is a potent small molecule inhibitor of NUPR1 (Nuclear Protein 1), a stress-induced protein implicated in cancer cell survival and tumor progression. It binds to NUPR1 with a dissociation constant (Kd) of 2.1 μM and inhibits its function by blocking the translocation of NUPR1 from the cytoplasm to the nucleus, likely through competition with importins[7][1]. Mechanistically, ZZW-115 induces tumor cell death via necroptosis, apoptosis, and ferroptosis in a mitochondria-dependent manner[3][4][8]. Preclinical studies have demonstrated that treatment with ZZW-115 significantly reduces pancreatic intraepithelial neoplasia (PanINs) and blocks NUPR1-dependent stress granule formation in mouse models of pancreatic ductal adenocarcinoma[6]. The compound also leads to reactive oxygen species (ROS) accumulation followed by ferroptotic cell death. Its primary development focus is as an anticancer agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZZW-115.